NICE final guidance recommends anti-TNFs Humira and Remicade for Crohn's disease
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for health and Clinical Excellence, in the UK is recommending Abbott's Humira (adalimumab) and Schering-Plough's Remicade (infliximab, licensed from Johnson & Johnson) for the treatment of some Crohn's disease patients.